ReviewExpert review of vaccines2010
DNA vaccines for targeting bacterial infections.
Review in Expert review of vaccines, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.
- Evaluation of immune responses toFrontiers in veterinary science · 2022Pooled it
- Modern Strategies for Brucellosis Vaccination: From Traditional Approaches to Innovative Platforms.Vaccines · 2026Review
- Beyond Antibiotics: Alternative Strategies TargetingExpert reviews in molecular medicine · 2026Review
- Unraveling brucellosis: advances in pathogenesis, diagnostic strategies, therapeutic innovations, and public health perspectives.Frontiers in medicine · 2025Review
- Preclinical Development of a Novel Epitope-based DNA Vaccine Candidate against SARS-CoV-2 and Evaluation of Immunogenicity in BALB/c Mice.AAPS PharmSciTech · 2024Article
- Review
- Review
- An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines.Progress in biophysics and molecular biology · 2023Review
- Harnessing DNA for immunotherapy: Cancer, infectious diseases, and beyond.Advanced functional materials · 2022Article
- Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa.Nanomaterials (Basel, Switzerland) · 2022Review
- Ligand-protein interactions of plant-isolated (9z,12z)-octadeca-9,12-dienoic acid with Β-ketoacyl-Acp synthase (KasA) in potential anti-tubercular drug designing.Scientific African · 2021Article
- Biopolymer-based Carriers for DNA Vaccine Design.Angewandte Chemie (International ed. in English) · 2021Review
- A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development.ACS central science · 2021Article
- Vaccines: Underlying Principles of Design and Testing.Clinical pharmacology and therapeutics · 2021Article
- Considerations for Size, Surface Charge, Polymer Degradation, Co-Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases.Advanced nanobiomed research · 2021Article
- DNA vaccines against COVID-19: Perspectives and challenges.Life sciences · 2021Review
- Encapsulating Polyethyleneimine-DNA Nanoplexes into PEGylated Biodegradable Microparticles Increases Transgene Expression In Vitro and Reduces Inflammatory Responses In Vivo.AAPS PharmSciTech · 2021Article
- Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection.Advanced drug delivery reviews · 2021Review
- Synthetic SARS-CoV-2 Spike-Based DNA Vaccine Elicits Robust and Long-Lasting Th1 Humoral and Cellular Immunity in Mice.Frontiers in microbiology · 2021Article
- Developing Diagnostic and Therapeutic Approaches to Bacterial Infections for a New Era: Implications of Globalization.Antibiotics (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
DNA vaccination has been of great interest since its discovery in the 1990s due to its ability to elicit both humoral and cellular immune responses. DNA vaccines consist of a DNA plasmid containing a transgene that encodes the sequence of a target protein from a pathogen under the control of a eukaryotic promoter. This revolutionary technology has proven to be effective in animal models and four DNA vaccine products have recently been approved for veterinary use. Although few DNA vaccines against bacterial infections have been tested, the results are encouraging. Because of their versatility, safety and simplicity a wider range of organisms can be targeted by these vaccines, which shows their potential advantages to public health. This article describes the mechanism of action of DNA vaccines and their potential use for targeting bacterial infections. In addition, it provides an updated summary of the methods used to enhance immunogenicity from codon optimization and adjuvants to delivery techniques including electroporation and use of nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.